Navigation Links
GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Date:12/11/2007

PHILADELPHIA, Dec. 11 /PRNewswire-FirstCall/ -- The following is GlaxoSmithKline's (NYSE: GSK) response to the retrospective analysis by the Institute for Clinical Evaluative Sciences (ICES) titled "Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes".

GSK believes that the ICES retrospective analysis of the Ontario Drug Benefit (ODB) database has significant limitations and generates misleading conclusions regarding acute myocardial infarction and death. These conclusions are inconsistent with a more robust body of evidence from large, long-term, prospective, well-designed clinical studies, including ADOPT and RECORD.

-- These long-term trials in diabetic patients comparing rosiglitazone to

other oral anti-diabetic medicines show no increased risk for

cardiovascular events compared to other commonly used medications,

other than the well-known risk of congestive heart failure (CHF) with

thiazolidinedione (TZDs).

-- RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of

Glycaemia in Diabetes) was specifically designed to evaluate the

cardiovascular safety of rosiglitazone, and is therefore the most

robust data available. A recently published interim analysis for

myocardial infarction and death from cardiovascular causes, or from any

cause, showed no statistically significant difference between

rosiglitazone in combination with either metformin or sulfonylurea vs.

the active comparators of metformin plus sulfonylurea.

In addition, the RESULT clinical study specifically examined an elderly diabetic population, ages 59 to 89, in which 43 percent of the patients were gre
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
9. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
10. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... North Shore Towers, a luxury co-op community ... Energy, one of the nation’s leading combined heating and power ... its 43-year-old CHP system. The original CHP system had been ... extend the life of the plant, GI Energy was contracted ... heat recovery equipment, while maintaining continuous operation of the entire ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
(Date:7/31/2014)... Rancho BioSciences , the scientific ... Array Suite with tranSMART . Scientists that ... send data in tranSMART to Array Suite for further ... tranSMART including the new 1.2 release. Array Suite ... for the analysis of high dimensional quantification data, including ...
(Date:7/31/2014)... BOTHELL, Wash. , July 31, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s second quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Biology Technology:North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2
... , IRVINE, Calif. , April 26 ... products chemistry company which provides novel and innovative ingredients ... announced today the launch of pTeroPure™ pterostilbene(tero-STILL-bean). This exciting ... an exclusive worldwide license to all patent rights of ...
... SAN DIEGO , April 26 ... the discovery and development of RNA-targeted therapies, today announced ... research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type ... high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) ...
... 23 Asymchem Laboratories is proud to announce and welcome Dr. ... Huang as Director of Chemical Development, and Dr. Xiaojun Huang ... , , ... February 1, 2010 .  He brings extensive scientific and managerial experience in ...
Cached Biology Technology:ChromaDex Launches pTeroPure Pterostilbene 2ChromaDex Launches pTeroPure Pterostilbene 3ChromaDex Launches pTeroPure Pterostilbene 4ChromaDex Launches pTeroPure Pterostilbene 5Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 2Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 3Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 4Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 5Asymchem Laboratories Hires Three New Employees: Guojie Xu, Pingzhong Huang, and Xiaojun Huang 2
(Date:7/31/2014)... research, supported by the National Science Foundation (NSF), ... uniformly accelerates atmospheric warming, indicating instead that certain ... emit into the atmosphere. , The study, ... , focuses on thermokarst lakes, which occur as ... with melted fresh water, converting what was previously ...
(Date:7/31/2014)... A long-term follow-up study (HPV-023; NCT00518336) shows ... GlaxoSmithKline,s human papilloma virus (HPV) vaccine Cervarix. ... were followed for more than nine years, ... was 100%. This is the longest follow-up ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. ...
(Date:7/31/2014)... of animal models against the highly infectious and virulent ... disease that kills approximately 30,000 Americans annually. The research ... Immunity . , In the study, the vaccine ... toxins produced by C. difficile , as well ... that mimics the human disease, after only two immunizations. ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... PA, June 24, 2011 Adolescents who diet and ... behaviors and binge eating) carry these unhealthy practices into ... by University of Minnesota researchers and published in the ... American Dietetic Association . "The findings from the ...
... are widely recognized as significant environmental concerns in the ... major impact of landscape irrigation on their regional water ... in College Station, Texas, estimated that more than 24 ... annually for landscape irrigation alone. According to the ...
... June 23, 2011 UT Southwestern Medical Center researchers ... pathway in Huntington,s disease, a finding that may eventually ... the progression of degenerative nerve disorders. "Our studies ... treatment and possibly for other neurodegenerative diseases," said Dr. ...
Cached Biology News:Adolescents' dieting and disordered eating behaviors continue into young adulthood 2Adolescents' dieting and disordered eating behaviors continue into young adulthood 3Landscape coefficients prove useful for urban water conservation efforts 2Compound may provide drug therapy approach for Huntington's disease 2
... Columns are designed for the rapid purification of ... agarose gels. The DNA band is excised from ... Embedded within the base of the column are ... agarose and impurities back while allowing DNA to ...
... Ultra Agarose Spin Kit is an advanced system for ... purified DNA can be used directly for any downstream ... DNA is ready to use in 56 minutes ... used for TAE and TBE gels No specialised ...
This depletion cocktail is tailored to deplete IgE-bearing (I.e. basophils and mast cells) from whole blood...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: